Literature DB >> 27277462

Early ultrasonographic evaluation of tumor thrombus level during sunitinib therapy for renal cell carcinoma.

Futoshi Sano1, Syusei Fusayasu2, Shinji Otake2, Hiroyuki Yamanaka2, Tomoyuki Tatenuma2, Ryoko Sakata2, Kazuhide Makiyama2, Noboru Nakaigawa2, Masahiro Yao2, Yoshinobu Kubota2.   

Abstract

A 72-year-old man presenting with a 14-cm left renal mass, an inferior vena cava (IVC) tumor thrombus, and pulmonary metastases underwent renal mass biopsy that revealed clear cell renal cell carcinoma. Because of metastases and the extent of the tumor thrombus, sunitinib was administered, which resulted in a marked reduction in the tumor thrombus (from level III to level II after 11 weeks of treatment). Ultrasonography, preceding computed tomography, showed a slight shrinkage of the tumor thrombus level in the first 2 weeks. Therefore, ultrasound may be advantageous to monitor the IVC tumor thrombus level during the early phase of targeted therapy.

Entities:  

Keywords:  Molecular targeted therapy; Renal cell carcinoma; Tumor thrombus; Ultrasonography

Year:  2013        PMID: 27277462     DOI: 10.1007/s10396-013-0448-1

Source DB:  PubMed          Journal:  J Med Ultrason (2001)        ISSN: 1346-4523            Impact factor:   1.314


  12 in total

Review 1.  Contemporary management of renal tumors with venous tumor thrombus.

Authors:  Frédéric Pouliot; Brian Shuch; Jeffrey C Larochelle; Allan Pantuck; Arie S Belldegrun
Journal:  J Urol       Date:  2010-09       Impact factor: 7.450

2.  Progression of a caval vein thrombus in two patients with primary renal cell carcinoma on pretreatment with sunitinib.

Authors:  Axel Bex; Astrid A M Van der Veldt; Christian Blank; Martijn R Meijerink; Epie Boven; John B A G Haanen
Journal:  Acta Oncol       Date:  2010-05       Impact factor: 4.089

Review 3.  Multidetector computed tomography vs magnetic resonance imaging for defining the upper limit of tumour thrombus in renal cell carcinoma: a study and review.

Authors:  Nathan Lawrentschuk; Johan Gani; Richard Riordan; Steven Esler; Damien M Bolton
Journal:  BJU Int       Date:  2005-08       Impact factor: 5.588

4.  The impact of targeted molecular therapies on the level of renal cell carcinoma vena caval tumor thrombus.

Authors:  Nicholas G Cost; Scott E Delacroix; Joshua P Sleeper; Paul J Smith; Ramy F Youssef; Brian F Chapin; Jose A Karam; Stephen Culp; E Jason Abel; James Brugarolas; Ganesh V Raj; Arthur I Sagalowsky; Christopher G Wood; Vitaly Margulis
Journal:  Eur Urol       Date:  2011-02-23       Impact factor: 20.096

5.  A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ.

Authors:  Axel Bex; Christian Blank; Wim Meinhardt; Harm van Tinteren; Simon Horenblas; John Haanen
Journal:  Urology       Date:  2011-07-29       Impact factor: 2.649

6.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.

Authors:  Robert J Motzer; Jennifer Bacik; Barbara A Murphy; Paul Russo; Madhu Mazumdar
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

7.  Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma.

Authors:  E Jason Abel; Stephen H Culp; Nizar M Tannir; Surena F Matin; Pheroze Tamboli; Eric Jonasch; Christopher G Wood
Journal:  Eur Urol       Date:  2010-10-16       Impact factor: 20.096

8.  Surgical treatment of renal cancer with vena cava extension.

Authors:  R J Neves; H Zincke
Journal:  Br J Urol       Date:  1987-05

9.  Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.

Authors:  Robert C Flanigan; G Mickisch; Richard Sylvester; Cathy Tangen; H Van Poppel; E David Crawford
Journal:  J Urol       Date:  2004-03       Impact factor: 7.450

10.  Presurgical downstaging of vena caval tumor thrombus in advanced clear cell renal cell carcinoma using temsirolimus.

Authors:  Futoshi Sano; Kazuhide Makiyama; Tomoyuki Tatenuma; Ryoko Sakata; Hiroyuki Yamanaka; Syusei Fusayasu; Takashi Nakayama; Noboru Nakaigawa; Masahiro Yao; Yoshinobu Kubota
Journal:  Int J Urol       Date:  2012-11-27       Impact factor: 3.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.